B群脑膜炎球菌疫苗对淋病的有效性:一项回顾性研究
在Kaiser Permanente北加州2016—2021年电子健康记录中,纳入15—30岁人群,评估MenB-4C疫苗对淋球菌单纯感染的保护效果。仅调整种族/族裔的有限模型显示MenB-4C接种对淋球菌单纯感染有23%保护作用(APR=0.77,95%CI=0.64-0.99),但扩展模型调整其他潜在混杂因素后未观察到保护作用,对淋球菌/衣原体共感染亦未观察到保护作用。
要点
- 仅调整种族/族裔时,MenB-4C接种对淋球菌单纯感染有23%保护作用(APR=0.77,95%CI=0.64-0.99)。
- 扩展模型调整其他潜在混杂因素后,未观察到MenB-4C接种对淋球菌单纯感染的保护作用。
- 未观察到MenB-4C接种对淋球菌/衣原体共感染的保护作用。
核心结论
- MenB-4C接种对淋球菌单纯感染的保护作用独立于种族/族裔,但纳入其他潜在混杂因素后该保护作用未再观察到,对淋球菌/衣原体共感染未观察到保护作用。
研究设计与样本
- 回顾性研究,基于Kaiser Permanente北加州2016—2021年电子健康记录,纳入15—30岁淋球菌单纯感染、衣原体单纯感染及淋球菌/衣原体共感染者。
- 共纳入68,454人,其中MenB-4C接种者558人(0.8%),共识别85,393例感染(淋球菌单纯感染13,000例、衣原体单纯感染68,008例、淋球菌/衣原体共感染4,385例)。
- 采用对数二项回归与广义估计方程计算调整患病率比(APR)及95%置信区间(CI)。
- 因担心接种者样本量小,分别使用仅调整种族/族裔的有限模型和调整其他潜在混杂因素的扩展模型估计效应。
主要发现
- 仅调整种族/族裔的有限模型中,MenB-4C接种对淋球菌单纯感染较衣原体单纯感染有23%保护作用(APR=0.77,95%CI=0.64-0.99)。
- 扩展模型调整其他潜在混杂因素后,未观察到MenB-4C接种对淋球菌单纯感染的保护作用。
- 未观察到MenB-4C接种对淋球菌/衣原体共感染的保护作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文提到对接种者样本量小的担忧,并因此分别采用有限模型和扩展模型估计效应。
- 原文结论指出需要临床试验的有效性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outer membrane vesicle (OMV) meningococcal serogroup B (MenB) vaccines might be protective against gonorrhea. We evaluated the effectiveness of MenB-4C, an OMV MenB vaccine, against gonorrhea. METHODS: We identified gonococcal mono-infections, chlamydial mono-infections, and gonococcal/chlamydial co-infections among persons aged 15-30 years in the electronic health records of Kaiser Permanente Northern California during 2016-2021. We determined MenB-4C vaccination status (vaccinated [≥1 MenB-4C vaccine dose] or unvaccinated [MenB-4C vaccine naïve]) at each infection. We used log-binomial regression with generalized estimating equations to calculate adjusted prevalence ratios (APR) and 95 % confidence intervals (CI) to determine if MenB-4C vaccination was protective against gonococcal mono-infections compared to chlamydial mono-infection. We also evaluated if MenB-4C vaccination was protective against gonococcal/chlamydial co-infections. Because of concerns with small sample size of vaccinated persons, we estimated effects using a limited model (adjusting for race/ethnicity only) and an expanded model (adjusting for additional potential confounders). RESULTS: Of 68,454 persons, we identified 558 (0.8 %) MenB-4C vaccinated persons and 85,393 infections (13,000 gonococcal mono-infections, 68,008 chlamydial mono-infections, and 4385 gonococcal/chlamydial co-infections). After adjusting for race/ethnicity, MenB-4C vaccination was 23 % protective against gonococcal mono-infection compared to chlamydial mono-infection (APR = 0.77, 95 % CI = 0.64-0.99) in the limited model but not in the expanded model. CONCLUSION: MenB-4C vaccination was protective against gonococcal mono-infection, independent of race/ethnicity. This protective effect was not observed when other potential confounders were included in the analysis. Protection against gonococcal/chlamydial co-infection was not observed. Efficacy data from clinical trials are needed.
引用
- Abara WE, Modaressi S, Fireman B, et al. Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: A retrospective study. Vaccine. 2024. PMID: 39260056. doi:10.1016/j.vaccine.2024.126312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。